HHE Report, No. HETA-81-322-1228, Mylan Pharmaceuticals, Morgantown, West Virginia.
Watanabe-AS; Patnode-R; Singal-M; Ferguson-RP
NIOSH 1982 Nov:16 pages
Exposures to chlorthalidone (77361) (CTD) were investigated on May 18, 19, 28 and 29, 1981 at Mylan Pharmaceuticals Company (SIC-2834), Morgantown, West Virginia. Evaluation was requested by a representative of the Oil, Chemical and Atomic Workers Union for 225 employees. Personal and area air samples were analyzed for CTD, dust, and methylene-chloride (75092) (MC). Medical questionnaires and tests were given to 10 CTD exposed workers and 10 comparisons. Total and respirable dust concentrations were 0.6 to 14.4 and 0.1 to exposure standard is given. Exposures to MC ranged from 1 to 25 parts per million (ppm), compared to NIOSH limit of 75ppm. CTD concentrations were from 1.1 to 2.3mg/m3: no exposure standard exists. Compared to comparisons CTD production workers had reduced orthostatic blood pressure, widening of pulse pressure, smaller decrease in serum glucose and no decrease in urinary sodium/potassium ratio. Blood concentrations of CTD were detected in 7 of 10 workers, but did not correlate to exposure concentrations. The authors conclude that workers can absorb CTD, and that some workers may be sensitive to it. They recommend minimizing exposure and establishing exposure standards for CTD.
NIOSH-Author; NIOSH-Health-Hazard-Evaluation; Hazards-Confirmed; Industrial-hygiene; Worker-health; Industrial-exposures; Pharmaceutical-industry; HETA-81-322-1228; NIOSH-Technical-Assistance-Report; Region-3;
Hazard Evaluation and Technical Assistance; Field Studies
NTIS Accession No.
Hazard Evaluations and Technical Assistance Branch, NIOSH, Cincinnati, Ohio, 16 pages, 7 references